Evolent Health Inc. (EVH)
NYSE:EVH
Want to see EVH full AI Analyst Report?
EVH Stock Chart & Stats
$2.84
<$0.01(0.08%)
At close: 4:00 PM EST
$2.84
<$0.01(0.08%)
Day’s Range― - ―
52-Week Range$2.10 - $12.07
Previous CloseN/A
Volume268.11K
Average Volume (3M)2.70M
Market Cap
$528.66M
Enterprise Value$1.34B
Total Cash (Recent Filing)$166.00M
Total Debt (Recent Filing)$985.42M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 05, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.68
Shares Outstanding112,481,064
10 Day Avg. Volume2,543,474
30 Day Avg. Volume2,695,168
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)0.24
P/FCF Ratio96.07
Enterprise Value/Market Cap2.54
Enterprise Value/Revenue0.71
Enterprise Value/Gross Profit5.04
Enterprise Value/Ebitda-4.28
Forecast
1Y Price Target
$5.69Price Target Upside100.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.17
Revenue Forecast (FY)$2.50B
Bulls Say, Bears Say
Bulls Say
Platform & Contract MomentumLarge new Performance Suite contracts and successful cross-sells demonstrate durable platform value and scale. Converting major imaging and specialty expansions into contracted revenue materially increases recurring fee streams, strengthens client stickiness, and creates a pipeline for multi-year revenue growth as integrations go live.
Improved Balance Sheet LeverageA materially lower debt load and substantially improved debt-to-equity provide financial flexibility to fund launches and absorb near-term reserve swings. With a sizable equity base, the company can prioritize execution and deleveraging without immediate refinancing pressure, supporting medium-term stability.
Positive Operating Cash FlowPositive operating cash flow combined with a recurring, membership- and volume-linked fee model supports ongoing operations and investment in technology and launches. While free cash flow is thin, steady OCF indicates the core services generate cash to fund incremental growth and operating needs over the medium term.
Bears Say
Weak Profitability & Large Net LossSustained negative margins and a large net loss erode shareholder equity and limit reinvestment capacity. Persistent unprofitability weakens returns on capital, increases the burden of funding growth initiatives, and leaves the business vulnerable if revenue mix or MER trends reverse, challenging durable margin recovery.
Thin And Volatile Free Cash FlowVery limited and erratic free cash flow constrains the company's ability to fund software development, launch reserves, and interest costs without tapping liquidity. Thin FCF reduces strategic optionality and raises sensitivity to operational setbacks or higher-than-expected launch costs over the next several quarters.
Exchange Membership & Specialty Revenue ExposureHeavy exposure to exchange membership dynamics and specialty enrollment creates structural revenue and reserving volatility. Disenrollment drives lower specialty volumes, higher servicing costs and reserve builds, and makes medical expense ratio management and revenue predictability more difficult for multiple quarters.
Evolent Health News
EVH FAQ
What was Evolent Health Inc.’s price range in the past 12 months?
Evolent Health Inc. lowest stock price was $2.10 and its highest was $12.06 in the past 12 months.
What is Evolent Health Inc.’s market cap?
Evolent Health Inc.’s market cap is $528.66M.
When is Evolent Health Inc.’s upcoming earnings report date?
Evolent Health Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 48 days.
How were Evolent Health Inc.’s earnings last quarter?
Evolent Health Inc. released its earnings results on May 07, 2026. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.049 by $0.029.
Is Evolent Health Inc. overvalued?
According to Wall Street analysts Evolent Health Inc.’s price is currently Undervalued.
Does Evolent Health Inc. pay dividends?
Evolent Health Inc. does not currently pay dividends.
What is Evolent Health Inc.’s EPS estimate?
Evolent Health Inc.’s EPS estimate is >-0.01.
How many shares outstanding does Evolent Health Inc. have?
Evolent Health Inc. has 112,481,064 shares outstanding.
What happened to Evolent Health Inc.’s price movement after its last earnings report?
Evolent Health Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.049. Following the earnings report the stock price went up 11.488%.
Which hedge fund is a major shareholder of Evolent Health Inc.?
Currently, no hedge funds are holding shares in EVH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.69 (100.26% Upside)
$5.69 (100.26% Upside)
Blogger Sentiment
Neutral
EVH Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 86.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.54%
12-Months-Change
Fundamentals
Return on Equity
-77.89%
Trailing 12-Months
Asset Growth
-29.19%
Trailing 12-Months
Company Description
Evolent Health Inc.
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
EVH Company Deck
EVH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally constructive operational picture: solid sequential revenue growth (ex-ECP), strong Performance Suite momentum with marquee client launches and two large new contracts, MER improvement, and continued AI automation progress. Counterbalancing these positives are meaningful near-term headwinds tied to exchange membership declines, temporary servicing and reserve-related cost pressures, a notable sequential decline in Specialty Tech & Services revenue, and elevated net leverage. Management reiterated full-year guidance and outlined expectations for MER peaking in Q3 with improving EBITDA cadence thereafter, signaling confidence in execution while acknowledging near-term uncertainty tied to exchange disenrollment and launch reserves.View all EVH earnings summariesEVH Stock 12 Month Forecast
Average Price Target
$5.69
▲(100.26% Upside)
Technical Analysis
Ownership Overview
2.40% Insiders
14.06% Mutual Funds
35.69% Other Institutional Investors
36.66% Public Companies and
Individual Investors